LT3978B - New pharmaceutical formulations - Google Patents

New pharmaceutical formulations Download PDF

Info

Publication number
LT3978B
LT3978B LTIP1714A LTIP1714A LT3978B LT 3978 B LT3978 B LT 3978B LT IP1714 A LTIP1714 A LT IP1714A LT IP1714 A LTIP1714 A LT IP1714A LT 3978 B LT3978 B LT 3978B
Authority
LT
Lithuania
Prior art keywords
methylthiazole
hydroxyethyl
chloro
treatment
prophylaxis
Prior art date
Application number
LTIP1714A
Other languages
English (en)
Lithuanian (lt)
Inventor
Bernard Robin Boar
Alan John Cross
Alfred Richard Green
Curt-Eric Hagberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of LTIP1714A publication Critical patent/LTIP1714A/xx
Publication of LT3978B publication Critical patent/LT3978B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
LTIP1714A 1990-08-15 1993-12-30 New pharmaceutical formulations LT3978B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations

Publications (2)

Publication Number Publication Date
LTIP1714A LTIP1714A (en) 1995-09-25
LT3978B true LT3978B (en) 1996-06-25

Family

ID=20380161

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP1714A LT3978B (en) 1990-08-15 1993-12-30 New pharmaceutical formulations

Country Status (26)

Country Link
US (1) US5385921A (es)
EP (1) EP0619734B1 (es)
JP (1) JP3094077B2 (es)
AT (1) ATE164066T1 (es)
AU (1) AU657490B2 (es)
BG (1) BG97446A (es)
CA (1) CA2088775A1 (es)
CZ (1) CZ279586B6 (es)
DE (1) DE69129126T2 (es)
DK (1) DK0619734T3 (es)
ES (1) ES2114891T3 (es)
FI (1) FI930608L (es)
HU (1) HUT65821A (es)
IE (1) IE912818A1 (es)
IL (1) IL99169A (es)
IS (1) IS3743A7 (es)
LT (1) LT3978B (es)
LV (1) LV10921B (es)
NO (1) NO303447B1 (es)
NZ (1) NZ239329A (es)
PT (1) PT98688B (es)
RO (1) RO112994B1 (es)
RU (1) RU2093155C1 (es)
SE (1) SE9002659D0 (es)
SK (1) SK8793A3 (es)
WO (1) WO1992003134A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901658D0 (sv) * 1999-05-06 1999-05-06 Astra Ab New formulation
SE9904177D0 (sv) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
WO2002083863A2 (en) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
CN103772313B (zh) * 2014-01-02 2015-10-14 郑桂富 一种4-甲基-5-(2-羟乙基)噻唑的合成方法
CN112262814A (zh) * 2020-10-26 2021-01-26 宜宾学院 油樟叶渣发酵床养鸡方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230370A2 (en) 1986-01-14 1987-07-29 MERCK SHARP & DOHME LTD. Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825966A1 (de) * 1978-06-14 1980-01-03 Basf Ag Saures galvanisches nickelbad, das sulfobetaine als glanz- und einebnungsmittel enthaelt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230370A2 (en) 1986-01-14 1987-07-29 MERCK SHARP & DOHME LTD. Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B. J. ALPS: "Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolian gerbil", BR J PHARMACOL., 1988, pages 877 - 883
ENDE E. ET AL.: "Urinary metabolites of chlormethiazole", ARZNEIMITTEL FORSCH, 1979, pages 1655 - 1658
GILL R, FOSTER AC, WOODRUFF GN.: "Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil", J NEUROSCI., 1987, pages 3343 - 3349
OFFEN CP, FREARSON MJ, WILSON K, BURNETT D.: "4,5-Dimethylthiazole-N-oxide-S-oxide: a metabolite of chlormethiazole in man", XENOBIOTICA, 1985, pages 503 - 511
PAL R, SPITELLER G.: "Thiomethylation and thiohydroxylation--a new pathway of metabolism of heterocyclic compounds", XENOBIOTICA, 1982, pages 813 - 820

Also Published As

Publication number Publication date
EP0619734A1 (en) 1994-10-19
BG97446A (bg) 1994-03-24
PT98688A (pt) 1992-07-31
NO930452L (no) 1993-02-09
NO303447B1 (no) 1998-07-13
JP3094077B2 (ja) 2000-10-03
FI930608A7 (fi) 1993-02-11
IL99169A0 (en) 1992-07-15
IL99169A (en) 1995-10-31
CZ279586B6 (cs) 1995-05-17
RO112994B1 (ro) 1998-03-30
EP0619734B1 (en) 1998-03-18
AU8409291A (en) 1992-03-17
SK8793A3 (en) 1993-07-07
PT98688B (pt) 1999-01-29
NO930452D0 (no) 1993-02-09
IS3743A7 (is) 1992-02-16
LTIP1714A (en) 1995-09-25
DE69129126D1 (de) 1998-04-23
AU657490B2 (en) 1995-03-16
IE912818A1 (en) 1992-02-26
CA2088775A1 (en) 1992-02-16
CZ16693A3 (en) 1994-02-16
RU2093155C1 (ru) 1997-10-20
HUT65821A (en) 1994-07-28
NZ239329A (en) 1994-11-25
DE69129126T2 (de) 1998-07-23
DK0619734T3 (da) 1998-10-05
FI930608A0 (fi) 1993-02-11
US5385921A (en) 1995-01-31
LV10921B (en) 1996-08-20
SE9002659D0 (sv) 1990-08-15
ATE164066T1 (de) 1998-04-15
JPH06500097A (ja) 1994-01-06
ES2114891T3 (es) 1998-06-16
FI930608L (fi) 1993-02-11
HU9300388D0 (en) 1993-04-28
WO1992003134A1 (en) 1992-03-05
LV10921A (lv) 1995-12-20

Similar Documents

Publication Publication Date Title
RU2379300C2 (ru) Ингибиторы gsk-3
EP0811623B1 (de) Xanthinverbindungen mit terminal aminierten Alkinol-Seitenketten
US4304782A (en) Psychotropic deuterated derivatives of phenylhydantoin and pharmaceutical compositions comprising such derivatives
HU188058B (en) Process for preparing chyralic benzyl-mercapto-propionil-amino derivatives
DE3876402T2 (de) N-(2-alkyl-3-mercapto-1,5-dioxoalkyl)glycinamid-derivate und deren verwendung als kollagenase-inhibitoren.
CA1294276C (en) Benzothiazine dioxide derivatives
RU2093155C1 (ru) Применение 5-[2-хлор-1-гидроксиэтил]-4-метилтиазола для снижения поражения нейронов, подавления конвульсий и снижения двигательной активности
PL179021B1 (pl) Nowa pochodna (1-fenylo-1-heterocyklo)alkanu,sposób wytwarzania nowej pochodnej (1-fenylo-1-heterocyklo)alkanui kompozycja farmaceutyczna PL PL PL PL PL
EP0475214B1 (en) Caffeic acid derivatives and pharmaceutical compositions containing the same
JP2011500641A (ja) 医薬用途の新規なスルファメート化合物
LU86405A1 (fr) Derive antipsychotique du benzisothiazole s-oxyde
CN107434799B (zh) 一种2-氨基-3-取代巯基丙酸酯衍生物，制备方法及其应用
EP0304222A2 (en) Amino-2-hydroxypropyloximino-heterocycle beta blockers
CA2432959A1 (fr) Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
EP0337350B1 (en) Use of dimethylheptylphenyl butanoyl ethanolamine in treatment of hyperuricemia
JPH0138089B2 (es)
JPS58208256A (ja) α−メチル−３，４−ジヒドロキシフエニルアラニン誘導体の製法
KR20010041661A (ko) 세포분열 억제제
CN118063450A (zh) 芳基磺酰胺类化合物及其制法和药物用途
WO2000014073A1 (fr) Derives de la benzodiazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicaments et compositions
Attia et al. Research Article Anticonvulsant Potential of Certain New (2E)-2-[1-Aryl-3-(1H-imidazol-1-yl) propylidene]-N-(aryl/H) hydrazinecarboxamides
JPWO1995001352A1 (ja) チアゾリジン誘導体及びそれを含有する医薬
JPH0584317B2 (es)

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 19971230